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Abstract 
Objective 
Minimal literature exists investigating changes in inflammation with respect to the main 
nasal cavity (MNC) and paranasal sinuses (PS) before and after maximal medical therapy 
(MMT) for chronic rhinosinusitis (CRS).   We hypothesized that MMT produces a 
differential level of change in the volume of air space in the MNC and PS, and that 
resolution of mucosal disease associated with the osteomeatal complex (OMC) influences 
clinical response to MMT. 
Study Design   
Retrospective study of 12 pre- and post-MMT sinus-CT scans from 6 subjects with CRS, 
of which three succeeded and three failed therapy. 
Methods    
Mimics™ was used to create 3D-models of the MNC and PS, and then analysis of the 
models was performed. 
Results 
Mean differences in the sinonasal volume were 7866.5 ± 4339.9 mm3 and 17869.10 ± 
19472.70 mm3, amongst the failures and successes, respectively.  There is wide 
variability in the contribution of PS and MNC airspace volume change to the overall 
change in the sinonasal volume.  In two subjects, the direction of volume change in the 
MNC and PS diverged with respect to the overall change in volume.  Line-of-sight 
analysis demonstrated that successful responders to MMT had more patent MNC with 
direct access to the OMC.    
Conclusions 
There is a differential contribution to sinonasal, airspace volume change after MMT, 
when comparing the MNC and PS.  Response to MMT may not be solely attributable to 
PS change and may include a function of MNC change.  Line-of-sight models suggest 
that direct access to the OMC may impact response to MMT. 
Keywords: Chronic Rhinosinusitis, Maximal Medical Therapy, Main Nasal Cavity, 
Paranasal Sinuses 
Level of Evidence: 2b 
Introduction 
 Before consideration of functional endoscopic sinus surgery (FESS), it is 
generally accepted that patients with chronic rhinosinusitis (CRS) undergo a trial of 
“maximal medical therapy” (MMT).1-3 Although variation exists with regard to the 
definition and duration of MMT, the mainstay of treatment focuses on oral antibiotics, 
topical intranasal steroids, and sinonasal saline irrigation, with possible systemic oral 
steroid therapy.1-3 In a survey, greater than half of otolaryngologists who responded used 
sinonasal saline irrigation, intra-nasal steroids, oral steroids, and oral antibiotics with 
widely varying treatment durations in greater than 50% of patients presenting for initial 
evaluation of CRS.1 Though many studies have confirmed the efficacy of MMT in the 
management of CRS, there is no agreed upon consensus regarding the most effective 
regiment.4-7 
 The goals in the treatment of CRS are reduction in inflammation of the sinonasal 
mucosa, improved mucociliary clearance of the paranasal sinuses, and enhanced 
sinonasal airflow through the main nasal cavity with associated improvement in clinical 
symptoms.2,4,8-11  Currently, there are a number of studies that have investigated the effect 
of FESS on the sinonasal cavity and implications for nasal irrigation and drug delivery.  
According to Wofford et al., who studied the effect of FESS on topical maxillary sinus 
drug delivery, FESS with larger maxillary antrostomies allowed for improved topical 
drug delivery.12  Additionally, Frank et al. confirmed the enhancement in airflow 
particularly in the maxillary sinus that was associated with improvement in patient 
quality of life as well based on symptom questionnaires.13 
The majority of literature in the study of the sinonasal cavity of CRS patients has 
primarily focused on pre- and post-surgical evaluation of the main nasal cavity (MNC) 
and paranasal sinuses (PS).  However, scant literature exists investigating changes in the 
MNC and PS before and after MMT for CRS, and whether such changes are differential .  
In addition, it is unclear whether certain disease patterns influence clinical success or 
failure of MMT.  According to Lal et al., clinical predictors of failure of medical therapy 
for patients with CRS included higher patient scores of facial pressure and significant 
endoscopic mucosal inflammation.4 However, given that computed-tomography (CT) 
analysis generally provides the most comprehensive and objective method of assessing 
sinonasal disease severity, assessment of sinus CT’s can often provide important 
information regarding change after treatment intervention.14   
 Therefore, we sought to differentially compare and analyze changes in the MNC 
and PS using three-dimensional (3D) reconstructed models of sinus CT scans of patients 
obtained before and after MMT for CRS.  In this preliminary study of six patients,  we 
hypothesized that there is a differential level of change in the volume of air space and 
mucosal inflammation in the nasal cavity when compared to the paranasal sinuses, and 
that these volumes of change distinctively impact the overall change in air space after 
medical therapy.  Secondly, we hypothesized that resolution of mucosal disease 
associated with the osteomeatal complex (OMC) influences clinical response to MMT 
and direct visualization of the OMC from the external nares may be associated with 
success of MMT. 
 
 
Materials and Methods 
 After approval from the Institutional Review Board, sinus-CT scans from subjects 
with CRS who had been treated with MMT were obtained.  Patients from the subject pool 
had been diagnosed with CRS based on clinical criteria and none had prior surgical 
therapy.9  Of note, patients in the subject pool were previously enrolled in a prospective, 
randomized cohort study evaluating MMT, however this study is a retrospective analysis 
of the sinus CT scans that were obtained as part of the prior study protocol.5  MMT for 
these patients was defined as an oral antibiotic course, intra-nasal steroid treatment with 
Flonase, and sinonasal saline irrigation.  Prior to initiation of treatment and at the end of 
the treatment course, sinus CT scans were obtained. Additionally, rhinosinusitis disability 
index (RSDI) scores were obtained pre and post-therapy as a subjective measure of 
symptom improvement, and Lund-McKay (LM) scores were obtained from all sinus CT 
scans as part of an objective measure of change. A total of 12 CT scans were chosen for this preliminary evaluation.  Of these 12 scans, 6 sinus CT scans represented pre and post-therapy scans from patients who were deemed clinically successful responders to MMT.  Conversely, the remaining 6 sinus CT scans represented pre- and post-therapy scans from patients who were deemed clinical failures to MMT and would require surgical intervention.  Successful response or failure to MMT was determined based on clinical decision utilizing subjective and objective scoring measures including RSDI and LM scores, in addition to global patient symptoms.  Next, Mimics 18.1™ (Materialise, Inc., Plymouth, MI, USA) was used to create 
anatomically realistic three-dimensional (3D) reconstructions of the MNC and PS 
airways from the pre- and post-therapy CT scans. In each scan, the airspace was selected 
by setting a maximum threshold of -300 to -351 Hounsfield units based on visual 
inspection. The resulting pixel selection was then hand-edited to achieve anatomical 
accuracy and to separate the PS from the MNC (Fig. 1).  Volumetric analysis was then 
performed on the nasal air spaces of the pre- and post-therapy sinus CT 3D models, as a 
negative correlate of airway obstruction, purulence, and swelling associated with mucosal 
inflammation.  Of note, prior to the volumetric study, the effect of nasal cycling in the CT 
analysis was accounted for by comparing the pre and post-CT scans and ensuring for no 
unilateral changes that may confound analysis.   Mimics™ was also used to coregister 
pre-and post-therapy sinus CT scans for direct comparison of overlaid 3D reconstruction 
contours to assess direct changes in MNC structures including the turbinates and access 
to the osteomeatal complex (OMC). 
The 3D reconstructions were then exported from Mimics™ in stereolithography 
file format and imported into the computer-aided design and meshing software ICEM-
CFD™ 15.1 (ANSYS, Inc., Canonsburg, PA, USA).  Within this software, study of the 
OMC was performed via “line-of-sight” analysis.  The “line-of-sight” analysis was 
performed by computational rotation of the sinus CT models to re-create how and if the 
OMC could be visualized via the external nares. The centroid (center-of-mass) of each of 
the bilateral nasal planes was first obtained. With the head in an upright position, each 
side of the nasal vestibule was cut by a horizontal plane (roughly parallel to the hard 
palate) at a positive vertical distance of 5 mm from the nostril centroid on that side (Fig 
1).  This distance simulated the viewpoint of a nasal speculum or the approximately 
position of the tip of a nasal spray bottle. The bilateral OMCs were marked with points 
(Fig. 1) and visualization of these points from the cut vestibular areas was used to 
compute a line-of-sight grade (Fig. 1). An objective scoring system was devised on scale 
of 1-5. A score of 1 indicated full visualization of the OMC, where as a score of 5 
indicated zero visualization of the site. Varying degrees of visualization were scored in 
between with the lower numbers correlating with better visualization. Each pre-treatment 
model was subject to a “line-of-sight” analysis from the left nare and the right nare. The 
scores were combined and compared between the medical successes and failures.   
 
Results 
The selected cohort included three clinical successes and three clinical failures of 
MMT for CRS. RSDI and LM scores worsened or remained the same after MMT in three 
subjects (Table 1).  Conversely, RSDI and LM scores overall improved or remained the 
same after MMT in three subjects (Table 1). Importantly, all failure patients in the cohort 
required FESS to address CRS symptoms.  
There was a mean increase in the sinonasal airspace volume in the clinical success 
group when combining the volume of the MNC and PS and a mean decrease in the 
clinical failures group (Tables 2, 3).  Using 3D reconstructive techniques, this change was 
captured and used to analyze the MNC and PS separately (Fig, 2).  In the three failures, 
there was an average decrease in the airspace volume of the MNC and PS of 4043.4 ± 
3092.9 and 4118.7 ± 6331.5, respectively (Table 3).  In the three successes, there was an 
average increase in the airspace volume of the MNC and PS of 3805.8 ± 8046.0 and 
13701.5 ± 17574.8, respectively (Table 3). Of note, in each outcome group, two of the 
three subjects had consistent and expected directions of volume change of the MNC and 
PS.  However, in each outcome group, there was one subject whose direction of volume 
of change in the MNC and PS diverged with respect to the overall change in the sinonasal 
airspace volume.  In the success group, the volumetric analysis of subject 6, whose total 
sinonasal volume increased, demonstrated an unexpected decrease in the MNC volume, 
and in the failure group, the volumetric analysis of subject 1, whose total sinonasal 
airspace volume decreased, demonstrated an unexpected increase in the PS volume 
(Table 2).    Of note, when individually examining each patient, there is wide variability 
in the contribution of PS and MNC airspace volume change to the overall change in the 
sinonasal airspace volume.  With regard to the nasal turbinates, changes in turbinate 
hypertrophy were noticed throughout, but did not correlate with clinical response to 
MMT. 
From the overlay analysis, OMC patency was achieved or there was noticeable 
reduction in inflammation surrounding the complex itself in the success group (Fig. 3A).  
However, despite MMT, there was worsening of mucosal obstruction at the OMC or no 
improvement in mucosal inflammation surrounding the OMC in the three failures (Fig. 
3B). 
Visualization of the OMC using digitally created “line-of-sight” demonstrated 
that successful responders to MMT had more patent MNC with direct access to the OMC 
(Fig. 4). The three patients with medical success had line-of-sight scores of 2, 5, and 7 
with an average score between the three of 4.67 (Table 4). As anticipated, those who 
failed medical management had higher line-of-sight scores of 6, 9, and 9 with an average 
score of almost double, 8.0 (Table 4). 
 
Discussion  
Although there is a general consensus that MMT should be attempted prior to 
consideration of FESS, a recent systematic review showed that there is no definitive 
guideline on what constitutes MMT and only 21% of included studies demonstrated 
explicit MMT criteria that are necessary to fail prior to offering FESS.8 Additionally, 
though there is demonstrated benefit, the direct impact of MMT on the sinonasal cavity 
remains unclear.11  In conjunction, few studies have addressed differential impact of 
medical therapy for CRS on the MNC when compared to PS, and whether certain disease 
patterns lead to more medically refractory disease. 
3-D reconstructions of sinus CT scans from six CRS patients before and after 
MMT allowed for review of specific anatomic changes in the sinonasal cavity prior to 
MMT.  The total sinonasal volume increased in all three clinical successful responders 
and decreased in all three clinical failures.  These volumetric changes are consistent with 
predicted CT changes of the two cohorts, as generally enlargement of the airspace 
volume of the sinonasal cavities post-therapy is indicative of decreased mucosal 
inflammation and thus improvement in sinonasal symptoms as seen on RSDI scores.  
However, once the PS were separated from the MNC, there appeared to be an interesting 
divergence in findings in addition to differential impact of each the MNC and PS to the 
overall volume change.   
 First, amongst the success group, the direction of volume change of the PS and 
MNC was congruent with the general increase in overall sinonasal volume in two 
subjects.  However, even amongst these two subjects, there is a notable difference in how 
much PS compared to the MNC volume change contributes to the overall sinonasal 
volume change, wherein one subject the PS volume change is the dominant factor 
compared the MNC volume change being the dominant factor for the other patient.  
When comparing the pre and post-therapy LM and RSDI scores for these patient, there 
appeared to be a greater improvement in the RSDI score for the patient whose PS volume 
change seemed to be primary driver of sinonasal volume increase compared to the other 
patient in MNC volume change was the primary driver.  Interestingly, in the third success 
patient with diverging changes, whose PS volume increased while the MNC volume 
decreased, the total sinonasal volume change was lower, however, the patient’s symptom 
scores on the RSDI demonstrated significant improvement.  Although limited by sample 
size, this data suggests that there may be a differential impact of MMT on the PS and 
MNC.  Given incongruity amongst the patients’ changes, it is difficult to state whether 
changes in the MNC vs. the PS have a more clinical impact on response to MMT. 
 Similarly, in the failure group, the direction of volume change of the PS and MNC 
was congruent with the general decrease in overall sinonasal volume in two subjects.  
Again, even amongst these two subjects, there is a notable difference in how much PS 
compared to the MNC volume change contributes to the overall sinonasal volume 
change.  Interestingly amongst these two subjects, there was no difference in the pre- and 
post-therapy LM scores, showing that the sensitivity of the LM score to subtle sinonasal 
changes is lower.  The third patient of the failure cohort also interestingly demonstrated 
diverging changes in the volume of the MNC compared to the PS with respect to overall 
sinonasal volume change, wherein there was a small increase in PS volume compared to 
a larger decrease in MNC volume that was the primary driver. This data demonstrates 
differential impact of MMT on the MNC vs. the PS, but without significant antecedent 
literature investigating the direct impact of MMT on the sinonasal cavity, it is difficult to 
assess how this impacts response to medical treatment. 
 The osteomeatal complex plays a pivotal role in CRS given its physiologic 
function as a common, sinus drainage pathway and association with increased disease 
burden.15 Upon performing overlay analysis, amongst the clinical failures, there was 
either no change or clinical worsening of the mucosal inflammation in the MNC, 
particularly at the level of the OMC.  However, amongst the successful responders, there 
was either no change or clinical improvement in the mucosal inflammation surround the 
OMC.    
Lastly, as intranasal steroid spray is an essential component of MMT, the “line of 
sight” analysis provided information regarding the effect of medical management of 
CRS.  Although the sample sizes of the cohorts are low, improved visualization of the 
OMC from the nares theoretically increases the effectiveness of MMT when considering 
the use of intranasal steroid sprays.  Also, given that all of the three successful patient 
responders to MMT demonstrated improved “line of sight” to the OMC whereas failure 
subjects demonstrated poor “line of sight” to the OMC, based on study of the pre-
operative CT scans, a direct route for drug application may predispose patients to 
increased responsiveness to MMT and less likely to require operative intervention. 
Importantly, there are limitations to note.  Given the small sample size in both 
cohorts, it is difficult to make population based inferences about responsiveness to MMT. 
Secondly, when separating the PS from the MNC, there is no standardized method of 
separating sinuses from the nasal cavity, thus there is some variability noted between 3D 
reconstructions.  After denoting differential change in the MNC and PS volume in 
patients after MMT for CRS, the next step in elucidating the effect of MMT on the 
sinonasal cavity is to perform computational fluid dynamics (CFD) analysis on these 
patients’ CD.12,16  Through CFD, differential change on the nasal airflow within the MNC 
and PS can be studied to determine if MMT has a direct impact on nasal airflow and how 
clinical responders differ from clinical failures.    
  
Conclusion 
This study demonstrated that MMT has a definitive impact on changes in the 
sinonasal cavity, including volumetric changes in the airspace of the MNC and PS and 
inflammation surrounding the OMC, a critical determinant of disease burden in CRS.  Of 
note, there appears to be a differential contribution to the sinonasal, airspace volume 
change after MMT, when comparing the MNC and PS.  Though volumetric analysis 
suggested that the MNC changes as well as sinus patency, this should be further studied 
for potential differential changes in a larger cohort.  Overlay analysis showed that OMC 
patency improvement was consistent with good patient outcomes of MMT.  Thus, 
success or failure of MMT may not be solely attributable to paranasal sinus change and 
may include a function of nasal cavity change.  Lastly, line-of-sight analysis suggested a 
potential new predictor of MMT success in patients presenting with CRS, however, 
further investigation of anatomic changes after MMT is required in a larger study group. 
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Figure and Table Legend 
Figure 1:  Line of Sight Methodology  
Line-of-sight models demonstrating methodology for calculating OMC visualization.  
1A. Line-of-sight analysis of the left nostril shows an example of N(Y) or approximately 
50% visualization of the osteomeatal complex (OMC). 1B. There is a fragment of OMC 
visible within the left nostril (arrow); this was scored as a (N). 1C: Full visualization of 
bilateral OMC, scored as Y bilaterally.” 
 
Figure 2:  3D-Reconstructions of the Airspace of the Sinonasal Cavity  
3D-reconstructions of the air space of the nasal cavity and paranasal sinuses from pre- 
and post-therapy sinus CT-scans that were performed on patients who had undergone 
maximal medical therapy (MMT) for CRS.  1A. Reconstructed models from subject 1 
that demonstrates decrease in sinonasal volume in patient deemed clinical failure. 1B. 
Reconstructed models from subject 4 that demonstrate an increase in sinonasal volume in 
patient deemed successful responder to MMT. 
 
Figure 3:  Overlay Analysis of the Airspace of the Main Nasal Cavity 
Using overlay analysis of the airspace of the main nasal cavity, the airspace outlines of 
the pre- and post-therapy CT scans were superimposed on each other to demonstrate 
differential change in mucosal inflammation and the turbinates. 1A. Clinical worsening 
of mucosal inflammation in the main nasal cavity and OMC, where pre-therapy (red) 
outline demonstrates greater airspace volume compared to the post-therapy (blue) outline. 
1B. Clinical improvement in mucosal inflammation in the main nasal cavity and towards 
the OMC, where post-therapy (blue) outline demonstrates greater airspace volume 
compared to the pre-therapy (red) outline. 
 
Figure 4: OMC Visualization via Analysis of 3D-Reconstructions 
Manipulation of 3D-reconstrutions demonstrating view of the OMC from the external 
nares.  Upon manipulation of the 3D-models, it was seen that patients with successful 
response to MMT had a direct line-of-sight and access to the OMC when compared to 
patients who had failed MMT.  4C.  Direct view of the mucosal region overlying the 
OMC (dots) in subject 6, a successful, clinical responder to MMT.  4D. No direct 
visualization of the sinonasal region overlying the OMC in subject 1, a clinical failure 
after MMT.   
 
Table 1:  RSDI and LM Scores of Subject Cohorts of Failures and Successful 
Responders Clinical Responders to MMT 
RSDI- Rhinosinusitis Disability Index.  LM- Lund-Mackay 
 
Table 2:  Total Volumes of the Main Nasal Cavity and the Paranasal Sinus Air 
Space Before and After MMT in the Clinical Success and Clinical Failure Groups 
 
Table 3:  Mean Differences Between the Pre- and Post-Therapy Sinonasal Airspace 
Volumes of the Clinical Success and Clinical Failure Groups 
 
 
Table 4:  Line of Sight Analysis 
LHS - Left Hand Side; RHS - Right Hand Side; Y - Full Visualization of the OMC; (Y) - 
Greater than 50% of OMC visualized; N(Y) - Half of OMC visualized; (N) - Less than 
50% of OMC visualized; N - No visualization of the OMC 
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Line-of-sight models demonstrating methodology for calculating OMC visualization.  
1A. Line-of-sight analysis of the left nostril shows an example of N(Y) or approximately 
50% visualization of the osteomeatal complex (OMC). 1B. There is a fragment of OMC 
visible within the left nostril (arrow); this was scored as a (N). 1C: Full visualization of 
bilateral OMC, scored as Y bilaterally.” 
 
Figure 2:  3D-Reconstructions of the Airspace of the Sinonasal Cavity  
3D-reconstructions of the air space of the nasal cavity and paranasal sinuses from pre- 
and post-therapy sinus CT-scans that were performed on patients who had undergone 
maximal medical therapy (MMT) for CRS.  1A. Reconstructed models from subject 1 
that demonstrates decrease in sinonasal volume in patient deemed clinical failure. 1B. 
Reconstructed models from subject 4 that demonstrate an increase in sinonasal volume in 
patient deemed successful responder to MMT. 
 
Figure 3:  Overlay Analysis of the Airspace of the Main Nasal Cavity 
Using overlay analysis of the airspace of the main nasal cavity, the airspace outlines of 
the pre- and post-therapy CT scans were superimposed on each other to demonstrate 
differential change in mucosal inflammation and the turbinates. 1A. Clinical worsening 
of mucosal inflammation in the main nasal cavity and OMC, where pre-therapy (red) 
outline demonstrates greater airspace volume compared to the post-therapy (blue) outline. 
1B. Clinical improvement in mucosal inflammation in the main nasal cavity and towards 
the OMC, where post-therapy (blue) outline demonstrates greater airspace volume 
compared to the pre-therapy (red) outline. 
 
Figure 4: OMC Visualization via Analysis of 3D-Reconstructions 
Manipulation of 3D-reconstrutions demonstrating view of the OMC from the external 
nares.  Upon manipulation of the 3D-models, it was seen that patients with successful 
response to MMT had a direct line-of-sight and access to the OMC when compared to 
patients who had failed MMT.  4C.  Direct view of the mucosal region overlying the 
OMC (dots) in subject 6, a successful, clinical responder to MMT.  4D. No direct 
visualization of the sinonasal region overlying the OMC in subject 1, a clinical failure 
after MMT.   
 
Table 1:  RSDI and LM Scores of Subject Cohorts of Failures and Successful 
Responders Clinical Responders to MMT 
RSDI- Rhinosinusitis Disability Index.  LM- Lund-Mackay 
 
Table 2:  Total Volumes of the Main Nasal Cavity and the Paranasal Sinus Air 
Space Before and After MMT in the Clinical Success and Clinical Failure Groups 
 
Table 3:  Mean Differences Between the Pre- and Post-Therapy Sinonasal Airspace 
Volumes of the Clinical Success and Clinical Failure Groups 
 
 
Table 4:  Line of Sight Analysis 
LHS - Left Hand Side; RHS - Right Hand Side; Y - Full Visualization of the OMC; (Y) - 
Greater than 50% of OMC visualized; N(Y) - Half of OMC visualized; (N) - Less than 
50% of OMC visualized; N - No visualization of the OMC 
 
  
Subject ID PRE LM POST LM PRE RSDI POST RSDI Failure/Success 
1 4 7 8 11 F 
2 12 12 62 69 F 
3 11 11 4 4 F 
4 6 2 39 10 S 
5 4 2 22 22 S 
6 11 8 57 0 S 
 
 
  
Subject 
ID 
Failure/  Difference* in Difference in Difference in 
Success  Total Volume Main Nasal Cavity Volume Sinus Volume 
1 F  -5151.9 -7580.7 2453.8 
2 F  -12871.9 -2701.1 -10178.1 
3 F  -5575.7 -1848.6 -4631.9 
4 S  39104.1 5135.2 33853.3 
5 S  13654.2 11104.2 1550.9 
6 S  849.0 -4822.1 5700.4 
*All differences are (Post MMT – Pre MMT). 
 
  
  Average Sinonasal Volume Difference* 
Average Main 
Nasal Cavity 
Volume Difference 
Average Paranasal 
Sinuses Volume 
Difference 
Failure Cohort -7866.5 ± 4339.9 -4043.4 ± 3092.9 -4118.7 ± 6331.5 
Success Cohort 17869.1 ± 19472.7 3805.8 ± 8046.0 13701.5 ± 17574.8 
*All differences are After MMT – Before MMT 
 
 Failures LHS Score RHS Score Total Score 
1 (N) 4 N 5 9 
2 (N) 4 N 5 9 
3 Y 1 N 5 6 
Successes LHS Score RHS Score Total Score 
4 N 5 (Y) 2 7 
5 N(Y) 3 (Y) 2 5 
6 Y 1 Y 1 2 
 
Scoring System 
Y 1 
(Y) 2 
N(Y) 3 
(N) 4 
N 5 
 
 




